Navigation Links
Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data,Selected for Scientific Highlights Program at the American Academy,of Neurology Meeting

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Mar 19, 2007 - Acorda Therapeutics (Nasdaq: ACOR) today announced that Andrew Goodman, M.D., Director of the Multiple Sclerosis Center at the University of Rochester, will present data from Acorda's MS-F203 Phase 3 clinical trial of Fampridine-SR in multiple sclerosis at the upcoming American Academy of Neurology (AAN) meeting. The platform presentation will take place on Wednesday May 2, 2007 at 4:15 pm Eastern Time (ET). This abstract was also selected to be part of the Scientific Highlights program, which spotlights the top five percent of the more than 1600 abstracts accepted for presentation at this meeting. The AAN meeting will take place at the Hynes Convention Center in Boston, MA.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics' operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeut
'"/>




Page: 1 2

Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting
3. Acorda Therapeutics to Host Analyst and Investor Reception
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
(Date:12/14/2009)... Dec. 14 Zargis Medical Corp., a ... ) and a spin-off from Siemens Corporate Research ... it has begun selling its award-winning Zargis Cardioscan(TM) ... Cardioscan and its accompanying Bluetooth®-enabled electronic stethoscope were ... "2009 Innovation of the Year." Cardioscan ...
(Date:12/14/2009)... NEW YORK, Dec. 14 Southridge LLC ... small-cap and micro-cap companies, is pleased to announce that ... can provide up to $15 million in equity financing ... ,, "Through the years of financing the growth of ... IMDS to continually produce new developments in the field ...
(Date:12/14/2009)... -- Cardium Therapeutics (NYSE Amex: CXM ) ... GAM501 (Ad5PDGF-B/Collagen) in the Treatment of Diabetic Ulcers," ... Industry Conference held December 10-13, 2009 in St. ... attended by top industry leaders and renowned researchers ... Dr. Barbara K. Sosnowski, Cardium,s Vice President of ...
Breaking Medicine Technology:Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2Southridge LLC Provides Funding Through Private Equity Agreement with Imaging Diagnostic Systems, Inc. 2Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 2Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 3Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 4Start the School Year Off Right With an Eggcellent Breakfast 54152 1Start the School Year Off Right With an Eggcellent Breakfast 54152 2Start the School Year Off Right With an Eggcellent Breakfast 54152 3Dendreon Reports Second Quarter 2009 Financial Results 13487 1Dendreon Reports Second Quarter 2009 Financial Results 13487 2Dendreon Reports Second Quarter 2009 Financial Results 13487 3Dendreon Reports Second Quarter 2009 Financial Results 13487 4Dendreon Reports Second Quarter 2009 Financial Results 13487 5Dendreon Reports Second Quarter 2009 Financial Results 13487 6Ingenuitys Technology Powers BD Cell Pathways Tool on New BD Biosciences Website 13485 1Ingenuitys Technology Powers BD Cell Pathways Tool on New BD Biosciences Website 13485 2
(Date:12/14/2009)... -- The National Organization for Rare Disorders (NORD) today ... lifetime and annual health insurance caps. In a ... distributed widely on Capitol Hill, NORD said the current ... caps to continue for most Americans, contrary to what ... reform and welcomes the promises made by President Obama ...
(Date:12/14/2009)... simple activities like housework, gardening replaced tube watching , , ... watching 25 or 26 hours of television a week ... to cut his tube time in half. , During ... calories each day, and not necessarily through strenuous exercise, ... of his newly freed time was spent reading and ...
(Date:12/14/2009)... -- Skilled nursing facilities (SNFs) in Ohio are making ... deal with a 92 percent increase in the state-imposed ... $12.01 per bed per day, scheduled for December 15. ... pay an additional $17,520 to the state each month, ... $438,365 yearly. ,, Nearly 96 percent of skilled nursing ...
(Date:12/14/2009)... Hemophilia Federation of America (HFA) expresses its concern ... Local 929 and the American Red Cross of ... on skilled workers to provide clean, safe blood ... such as clotting factor for use in treating ... Division of Blood Services at the American Red ...
(Date:12/14/2009)... linked to scans performed in 2007 , , MONDAY, Dec. ... patients to far more radiation than previously thought and in ... year, two new studies claim. , Based on the findings, ... of Internal Medicine , the study authors, joined by ... clinicians to limit radiation exposure to patients. , "CT has ...
Breaking Medicine News(10 mins):Health News:NORD Calls for Immediate End to Lifetime Insurance Caps 2Health News:Cutting TV Time Burns More Calories 2Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 2Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 3Health News:HFA Voices Blood Safety Concerns 2Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4
... to separate three-year-old girls who are joined at the head, ... swelling , a hospital spokeswoman said Tuesday. ... and have left the hospital to stay with their Romanian-born ... Rainbow Babies and Children's Hospital in Cleveland, Ohio. ...
... One can do nothing more than ironing ones own clothes ... colleague instead of e-mailing could be a sure way of ... of 173 southeast Queensland adults found the longer they spent ... on the phone rather than sitting the lower their ...
... track star teenager from a seemingly innocuous muscle cream, has ... . , Arielle Newman, 17, from Notre ... overdose of the muscle cream BenGay, which contains the active ... to soothe aching muscles after training sessions of sports. ...
... why sleep deprived people should never get behind the wheel, ... hamper the coordination of horizontal eye movements that is ... conducted on a group of 6 participants by Mark Chattington ... a winding route on a driving simulator, as a part ...
... al-Hajam carefully placed the glass jars over the slight incisions on ... In the ensuing vacuum , the thick dark blood slowly oozed ... ,"The Assyrians, the Chinese and the ancient Egyptians all used to ... he deftly drained a few more spots on his patient's back ...
... in a study that prenatal cocaine exposure renders students weaker at ... doctors gave attention tests to 415 African-American children, aged 5 to ... The mothers of 219 of the children had taken cocaine while ... of the mothers were poor and living in the Miami inner ...
Other Medicine News:Health News:Iron Clothes to Lower Blood Sugar Levels 2Health News:Teenagers Untimely Death Draws Attention To Safety Of Over The- Counter Drugs 2Health News:Ancient Healing Technique Gains New Popularity in Iraq 2Health News:Exposure to Cocaine During Pregnancy Weakens Kindergarten Kids Attention 2
IOL explanation snare for foldable lenses. Snare bisects lens for easy removal. Easy thumb activation. Replacement snares available E3526....
Pediatric size. Loops retract lids. Polished finish....
Adult size. Loops retract lids. Polished finish....
... Titanium. Designed to fixate ... procedures. The two-sided ring can ... the pointed or smooth side ... applying pressure to the eye ...
Medicine Products: